Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Operating Expenses: 2020-2025

Historic Other Operating Expenses for Apellis Pharmaceuticals (APLS) over the last 5 years, with Sep 2025 value amounting to $24.5 million.

  • Apellis Pharmaceuticals' Other Operating Expenses fell 26.90% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.4 million, marking a year-over-year increase of 17.15%. This contributed to the annual value of $117.7 million for FY2024, which is 101.20% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Other Operating Expenses of $24.5 million as of Q3 2025, which was up 80.03% from $13.6 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Other Operating Expenses registered a high of $50.0 million during Q2 2021, and its lowest value of $82,000 during Q2 2022.
  • For the 3-year period, Apellis Pharmaceuticals' Other Operating Expenses averaged around $22.6 million, with its median value being $22.4 million (2023).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Other Operating Expenses plummeted by 99.84% in 2022 and then spiked by 10,118.29% in 2023.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Other Operating Expenses stood at $30.1 million in 2021, then tumbled by 90.27% to $2.9 million in 2022, then soared by 580.75% to $19.9 million in 2023, then soared by 105.18% to $40.9 million in 2024, then dropped by 26.90% to $24.5 million in 2025.
  • Its Other Operating Expenses stands at $24.5 million for Q3 2025, versus $13.6 million for Q2 2025 and $34.4 million for Q1 2025.